MedTrace Logo

Study of Micafungin in Patients With Invasive Candidiasis or Candidemia

NCT00105144 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 611

Last updated 2014-09-18

No results posted yet for this study

Summary

The purpose of the study is to determine the safety and effectiveness of two dose levels of micafungin versus caspofungin in the treatment of proven invasive candidiasis or candidemia.

Conditions

  • Candidiasis
  • Candidemia

Interventions

DRUG

Micafungin

IV

DRUG

Caspofungin

IV

Sponsors & Collaborators

  • Astellas Pharma Inc

    lead INDUSTRY

Principal Investigators

  • Central Contact · Astellas Pharma US, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Primary Completion
2006-04-30
Completion
2006-04-30

Countries

  • United States
  • Austria
  • Belgium
  • Brazil
  • Canada
  • Croatia
  • Czechia
  • France
  • Germany
  • India
  • Netherlands
  • Poland
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00105144 on ClinicalTrials.gov